Product Code: 2849
The global blood platelets market is anticipated to register considerable gains through 2030. The industry expansion can be credited to the growing demand for platelet transfusions due to the rising cases of hemophilia. The constantly evolving patient safety standards have bolstered the realization for blood therapies that entail fewer complications, which shapes the industry outlook.
To that end, blood banks and healthcare units are increasingly investing in medical advancements to bring safe transfusion systems to their portfolio of services. The presence of government agencies that regulate blood and blood component collection is also shaping the industry scenario.
The high treatment costs associated with blood platelet therapies and awareness around the risk of infection are likely to hold back market revenues. The high associated costs make the treatment inaccessible to patients belonging to low socioeconomic background and low-income countries, which greatly limits the industry scope.
The overall blood platelets market landscape is bifurcated into segments such as platelet, application, end-use, and regional outlook.
Based on platelet, the market is segmented into whole blood derived platelets and apheresis derived platelets. Amongst them, whole blood derived platelets segment is witnessing surging demand owing to the crucial role they play in organ transplant and oncological procedures. WBD platelets are typically derived from four to five whole blood donations and are increasingly used in standard transfusion procedures. The collected platelets are frequently leukoreduced, pooled, and bacterially tested, which increases their usage in healthcare settings.
On the basis of application, the industry is divided into thrombocytopenia, hemophilia, platelet function disorders, perioperative Indications, and hemato-oncology. The market is projected to experience an elevated demand from the platelet function disorders segment, driven by the increasing prevalence of platelet disorders. The bleeding disorders accompanied by such defects increase the need for blood platelets to lessen the severity of the ailments.
Based on end use, the industry is categorized into hospitals and ambulatory centers. The hospital segment is set to gain considerable traction over 2022-2030, owing to increasing advancements in blood, collection, transfusion, and blood-related therapies. The higher level of expertise with respect to donor screening, data automation, and improved transfusion practices, sways patient inclination towards the hospital settings, fostering segment growth. The presence of highly trained staff also works in favor of the segment.
From a regional viewpoint, the market is segmented into North America, the Middle East and Africa, Latin America, Asia Pacific, and Europe. The Asia Pacific segment valuation is poised to surpass USD 1.5 billion owing to the rising presence of blood banks in the region. Their expansion is being driven by increasing investments towards the strengthening of healthcare infrastructure. Additionally, the emergence of NGO sector blood banks in countries like India, Bangladesh, and Pakistan is also anticipated to augment the industry expansion.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market definitions
- 1.2 Base estimates and working
- 1.3 Forecast parameters
- 1.4 Data validation
- 1.5 Data sources
- 1.5.1 Secondary
- 1.5.1.1 Paid sources
- 1.5.1.2 Unpaid sources
- 1.5.2 Primary
Chapter 2 Executive Summary
- 2.1 Blood platelets industry 360 degree synopsis, 2017 - 2030
- 2.2 Business trends
- 2.2.1 Platelet type trends
- 2.2.2 Product trends
- 2.2.3 End-use trends
- 2.2.4 Regional trends
Chapter 3 Blood Platelets Industry Insights
- 3.1 Industry segmentation
- 3.2 Industry landscape, 2017 - 2030 (USD Million)
- 3.3 Industry impact forces
- 3.3.1 Growth drivers
- 3.3.1.1 Increasing prevalence of chronic and blood-related disorders
- 3.3.1.2 Growing demand for blood transfusions
- 3.3.1.3 Rise in awareness regarding blood donations and platelets transfusions
- 3.3.1.4 Rising number of surgical procedures
- 3.3.2 Industry pitfalls & challenges
- 3.3.2.1 High risk of transmissions of infections
- 3.3.2.2 High cost of the treatment
- 3.4 Growth potential analysis
- 3.4.1 By platelet type
- 3.4.2 By application
- 3.4.3 By end-use
- 3.5 COVID- 19 impact analysis
- 3.6 Pricing analysis, 2017-2030
- 3.6.1 North America
- 3.6.1.1 U.S.
- 3.6.1.2 Canada
- 3.6.2 Europe
- 3.6.2.1 Germany
- 3.6.2.2 UK
- 3.6.2.3 France
- 3.6.2.4 Spain
- 3.6.2.5 Italy
- 3.6.3 Asia Pacific
- 3.6.3.1 China
- 3.6.3.2 Japan
- 3.6.3.3 India
- 3.6.3.4 Australia
- 3.6.3.5 South Korea
- 3.6.4 Latin America
- 3.6.4.1 Brazil
- 3.6.4.2 Mexico
- 3.6.4.3 Argentina
- 3.6.5 Middle East and Africa
- 3.6.5.1 South Africa
- 3.6.5.2 Saudi Arabia
- 3.6.5.3 UAE
- 3.7 Regulatory landscape
- 3.8 Reimbursement scenario
- 3.9 Gap analysis
- 3.10 Technology landscape
- 3.11 Porter's Analysis
- 3.12 Competitive landscape, 2021
- 3.12.1 Company matrix analysis, 2021
- 3.13 PESTLE Analysis
Chapter 4 Blood Platelets Market, By Platelet Type
- 4.1 Key segment trends
- 4.2 Whole blood derived platelets
- 4.2.1 Market size, by region, 2017 - 2030 (USD Million)
- 4.3 Apheresis derived platelets
- 4.3.1 Market size, by region, 2017 - 2030 (USD Million)
Chapter 5 Blood Platelets Market, By Product
- 5.1 Key segment trends
- 5.2 Hemophilia
- 5.2.1 Market size, by region, 2017 - 2030 (USD Million)
- 5.3 Thrombocytopenia
- 5.3.1 Market size, by region, 2017 - 2030 (USD Million)
- 5.4 Perioperative indications
- 5.4.1 Market size, by region, 2017 - 2030 (USD Million)
- 5.5 Platelet function disorders
- 5.5.1 Market size, by region, 2017 - 2030 (USD Million)
- 5.6 Hemato-oncology
- 5.6.1 Market size, by region, 2017 - 2030 (USD Million)
- 5.7 Others
- 5.7.1 Market size, by region, 2017 - 2030 (USD Million)
Chapter 6 Blood Platelets Market, By End-use
- 6.1 Key segment trends
- 6.2 Hospitals
- 6.2.1 Market size, by region, 2017 - 2030 (USD Million)
- 6.3 Ambulatory surgical centers
- 6.3.1 Market size, by region, 2017 - 2030 (USD Million)
- 6.4 Others
- 6.4.1 Market size, by region, 2017 - 2030 (USD Million)
Chapter 7 Blood Platelets Market, By Region
- 7.1 Key regional trends
- 7.2 North America
- 7.2.1 Market size, by country, 2017 - 2030 (USD Million)
- 7.2.2 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.2.3 Market size, by application, 2017 - 2030 (USD Million)
- 7.2.4 Market size, by end-use, 2017 - 2030 (USD Million)
- 7.2.5 U.S.
- 7.2.5.1 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.2.5.2 Market size, by application, 2017 - 2030 (USD Million)
- 7.2.5.3 Market size, by end-use, 2017 - 2030 (USD Million)
- 7.2.6 Canada
- 7.2.6.1 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.2.6.2 Market size, by application, 2017 - 2030 (USD Million)
- 7.2.6.3 Market size, by end-use, 2017 - 2030 (USD Million)
- 7.3 Europe
- 7.3.1 Market size, by country, 2017 - 2030 (USD Million)
- 7.3.2 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.3.3 Market size, by application, 2017 - 2030 (USD Million)
- 7.3.4 Market size, by end-use, 2017 - 2030 (USD Million)
- 7.3.5 Germany
- 7.3.5.1 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.3.5.2 Market size, by application, 2017 - 2030 (USD Million)
- 7.3.5.3 Market size, by end-use, 2017 - 2030 (USD Million)
- 7.3.6 UK
- 7.3.6.1 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.3.6.2 Market size, by application, 2017 - 2030 (USD Million)
- 7.3.6.3 Market size, by end-use, 2017 - 2030 (USD Million)
- 7.3.7 France
- 7.3.7.1 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.3.7.2 Market size, by application, 2017 - 2030 (USD Million)
- 7.3.7.3 Market size, by end-use, 2017 - 2030 (USD Million)
- 7.3.8 Spain
- 7.3.8.1 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.3.8.2 Market size, by application, 2017 - 2030 (USD Million)
- 7.3.8.3 Market size, by end-use, 2017 - 2030 (USD Million)
- 7.3.9 Italy
- 7.3.9.1 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.3.9.2 Market size, by application, 2017 - 2030 (USD Million)
- 7.3.9.3 Market size, by end-use, 2017 - 2030 (USD Million)
- 7.4 Asia Pacific
- 7.4.1 Market size, by country, 2017 - 2030 (USD Million)
- 7.4.2 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.4.3 Market size, by application, 2017 - 2030 (USD Million)
- 7.4.4 Market size, by end-use, 2017 - 2030 (USD Million)
- 7.4.5 China
- 7.4.5.1 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.4.5.2 Market size, by application, 2017 - 2030 (USD Million)
- 7.4.5.3 Market size, by end-use, 2017 - 2030 (USD Million)
- 7.4.6 Japan
- 7.4.6.1 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.4.6.2 Market size, by application, 2017 - 2030 (USD Million)
- 7.4.6.3 Market size, by end-use, 2017 - 2030 (USD Million)
- 7.4.7 India
- 7.4.7.1 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.4.7.2 Market size, by application, 2017 - 2030 (USD Million)
- 7.4.7.3 Market size, by end-use, 2017 - 2030 (USD Million)
- 7.4.8 Australia
- 7.4.8.1 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.4.8.2 Market size, by application, 2017 - 2030 (USD Million)
- 7.4.8.3 Market size, by end-use, 2017 - 2030 (USD Million)
- 7.4.9 South Korea
- 7.4.9.1 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.4.9.2 Market size, by application, 2017 - 2030 (USD Million)
- 7.4.9.3 Market size, by end-use, 2017 - 2030 (USD Million)
- 7.5 Latin America
- 7.5.1 Market size, by country, 2017 - 2030 (USD Million)
- 7.5.2 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.5.3 Market size, by application, 2017 - 2030 (USD Million)
- 7.5.4 Market size, by end-use, 2017 - 2030 (USD Million)
- 7.5.5 Brazil
- 7.5.5.1 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.5.5.2 Market size, by application, 2017 - 2030 (USD Million)
- 7.5.5.3 Market size, by end-use, 2017 - 2030 (USD Million)
- 7.5.6 Mexico
- 7.5.6.1 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.5.6.2 Market size, by application, 2017 - 2030 (USD Million)
- 7.5.6.3 Market size, by end-use, 2017 - 2030 (USD Million)
- 7.5.7 Argentina
- 7.5.7.1 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.5.7.2 Market size, by application, 2017 - 2030 (USD Million)
- 7.5.7.3 Market size, by end-use, 2017 - 2030 (USD Million)
- 7.6 Middle East & Africa
- 7.6.1 Market size, by country, 2017 - 2030 (USD Million)
- 7.6.2 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.6.3 Market size, by application, 2017 - 2030 (USD Million)
- 7.6.4 Market size, by end-use, 2017 - 2030 (USD Million)
- 7.6.5 South Africa
- 7.6.5.1 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.6.5.2 Market size, by application, 2017 - 2030 (USD Million)
- 7.6.5.3 Market size, by end-use, 2017 - 2030 (USD Million)
- 7.6.6 Saudi Arabia
- 7.6.6.1 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.6.6.2 Market size, by application, 2017 - 2030 (USD Million)
- 7.6.6.3 Market size, by end-use, 2017 - 2030 (USD Million)
- 7.6.7 UAE
- 7.6.7.1 Market size, by platelet type, 2017 - 2030 (USD Million)
- 7.6.7.2 Market size, by application, 2017 - 2030 (USD Million)
- 7.6.7.3 Market size, by end-use, 2017 - 2030 (USD Million)
Chapter 8 Company Profiles
- 8.1 Startegy dashboard, 2021
- 8.2 America's Blood Centers
- 8.2.1 Business Overview
- 8.2.2 Financial Data
- 8.2.3 Product Landscape
- 8.2.4 Strategic Outlook
- 8.2.5 SWOT Analysis
- 8.3 The American National Red Cross
- 8.3.1 Business Overview
- 8.3.2 Financial Data
- 8.3.3 Product Landscape
- 8.3.4 Strategic Outlook
- 8.3.5 SWOT Analysis
- 8.4 American Association of Blood Banks (AABB)
- 8.4.1 Business Overview
- 8.4.2 Financial Data
- 8.4.3 Product Landscape
- 8.4.4 Strategic Outlook
- 8.4.5 SWOT Analysis
- 8.5 Blood Centers of America
- 8.5.1 Business Overview
- 8.5.2 Financial Data
- 8.5.3 Product Landscape
- 8.5.4 Strategic Outlook
- 8.5.5 SWOT Analysis
- 8.6 Brazilian Red Cross
- 8.6.1 Business Overview
- 8.6.2 Financial Data
- 8.6.3 Product Landscape
- 8.6.4 Strategic Outlook
- 8.6.5 SWOT Analysis
- 8.7 Canadian Blood Services
- 8.7.1 Business Overview
- 8.7.2 Financial Data
- 8.7.3 Product Landscape
- 8.7.4 Strategic Outlook
- 8.7.5 SWOT Analysis
- 8.8 The European Blood Alliance
- 8.8.1 Business Overview
- 8.8.2 Financial Data
- 8.8.3 Product Landscape
- 8.8.4 Strategic Outlook
- 8.8.5 SWOT Analysis
- 8.9 French Red Cross
- 8.9.1 Business Overview
- 8.9.2 Financial Data
- 8.9.3 Product Landscape
- 8.9.4 Strategic Outlook
- 8.9.5 SWOT Analysis
- 8.10 German Red Cross
- 8.10.1 Business Overview
- 8.10.2 Financial Data
- 8.10.3 Product Landscape
- 8.10.4 Strategic Outlook
- 8.10.5 SWOT Analysis
- 8.11 Indian Red Cross Society
- 8.11.1 Business Overview
- 8.11.2 Financial Data
- 8.11.3 Product Landscape
- 8.11.4 Strategic Outlook
- 8.11.5 SWOT Analysis
- 8.12 Italian Red Cross
- 8.12.1 Business Overview
- 8.12.2 Financial Data
- 8.12.3 Product Landscape
- 8.12.4 Strategic Outlook
- 8.12.5 SWOT Analysis
- 8.13 Japanese Red Cross
- 8.13.1 Business Overview
- 8.13.2 Financial Data
- 8.13.3 Product Landscape
- 8.13.4 Strategic Outlook
- 8.13.5 SWOT Analysis
- 8.14 Red Cross Society of China
- 8.14.1 Business Overview
- 8.14.2 Financial Data
- 8.14.3 Product Landscape
- 8.14.4 Strategic Outlook
- 8.14.5 SWOT Analysis
- 8.15 OneBlood
- 8.15.1 Business Overview
- 8.15.2 Financial Data
- 8.15.3 Product Landscape
- 8.15.4 Strategic Outlook
- 8.15.5 SWOT Analysis
- 8.16 South African Red Cross Society
- 8.16.1 Business Overview
- 8.16.2 Financial Data
- 8.16.3 Product Landscape
- 8.16.4 Strategic Outlook
- 8.16.5 SWOT Analysis
- 8.17 Spanish Red Cross
- 8.17.1 Business Overview
- 8.17.2 Financial Data
- 8.17.3 Product Landscape
- 8.17.4 Strategic Outlook
- 8.17.5 SWOT Analysis